RecruitingPhase 2 / Phase 3NCT04613596
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Sponsor: Mirati Therapeutics Inc.
Athens, GA · Atlanta, GA · Carrollton, GA · +217 more sites